Analysis of Correlation and Agreement between the Uroflowmetry and the International Prostate Symptom Score in Patients after etropubic Radical Prostatectomy: A Multicenter Prospective Study

Análisis de correlación y concordancia entre la urofluometría y la escala internacional de síntomas prostáticos posterior a prostatectomía radical retropúbica: estudio multicéntrico prospectivo

Lynda Torres1, Angie Puerto2, Alejandra Bravo3, Miguel Acuña4, Juan Sánchez4, Olga Bejarano1
Paula Peña2, Juan Guillermo Cataño1

1Department of Urology, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá DC, Colombia
2Department of Urology, Pontificia Universidad Javeriana, Bogotá DC, Colombia
3Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá DC, Colombia
4Department of Urology, Fundación Cardioinfantil, Bogotá DC, Colombia

Abstract

Objectives Patients undergoing retropubic radical prostatectomy (RRP) may suffer from lower urinary tract symptoms (LUTS). We aim to characterize LUTS and to evaluate the correlation and agreement between uroflowmetry and the International Prostate Symptom Score (IPSS) in patients after RRP in two reference centers.

Methods An observational multicenter prospective study was conducted between December 2015 and September 2016. Patients with at least 12-months of follow-up after RRP were included; these were evaluated with uroflowmetry and the IPSS.

Results A total of 90 patients were included. The mean follow-up was of 54.6 months (standard deviation [SD] = 27.52), and the mean age was 65 (SD = 6.85) years old. The mean IPSS was 7.41 (SD = 6.29), with 33.3% (n = 54) of the patients with moderate symptoms and 6.7% (n = 6) with severe symptoms. A total of 50% (n = 45) of the patients had normal uroflowmetry. Patients with an abnormal/equivocal result...
in the uroflowmetry had a mean of 9.31 (SD = 7.03) points in the IPSS versus 5.51 (SD = 4.82) in patients with a normal uroflowmetry result (p < 0.01). The level of agreement between mild versus moderate-to-severe LUTS and normal uroflowmetry versus abnormal/equivocal was 61.1% (k = 0.22, p = 0.04). We found that a score ≥ 10 in the IPSS had a level of agreement of 65.6% (k = 0.31, p = 0.0004).

Conclusions We consider that although the IPSS cannot replace uroflowmetry and vice versa, these tests are complementary and may be useful tools in the evaluation of patients with LUTS after RRP.

Introduction

Retropubic radical prostatectomy (RRP) is among the alternatives of management with curative intention for localized prostate cancer or for the local control in nonlocalized disease, as it may decrease the risk of progression to metastasis and death associated with this entity. The objective of the surgery is the control of the disease, preservation of continence and of the sexual function.

Among the complications associated with RRP regarding urinary control is the bladder neck contracture that occurs in 0.5 to 10% of the patients. Additionally, incontinence can occur due to sphincteric involvement and detrusor hyperactivity in 5% of the cases. The sphincteric involvement is secondary to the surgical procedure, while hyperactivity is a bladder response to obstruction present in some patients with prostate cancer.

However, patients undergoing RRP may suffer from lower urinary tract symptoms (LUTS) different from urinary incontinence (UI). There are several studies reporting improvement of LUTS after RRP by improving bladder outlet obstruction, while others have reported the development of LUTS by factors inherent to the surgery.

Moreover, LUTS can be generated by factors inherent to the surgery. The pathophysiology of these symptoms may be secondary to the dissection of the posterior urethra, of the bladder neck and of the neurovascular bundles, which induces changes in the lower urinary tract secondary to denervation or ischemic changes during the surgical procedure, in addition to the anatomical changes caused by the urethrovesical anastomosis.

The IPSS is a valid and reliable instrument for measuring the severity of LUTS in a subjective way. Objective tools are also used to complement the results generated by the questionnaire, including noninvasive urodynamic tests, such as uroflowmetry.

To date, the proper way to evaluate LUTS in prostate cancer patients after surgery has not been established. We aim to characterize LUTS and to evaluate the correlation and agreement between uroflowmetry and the IPSS in patients after RRP in two reference centers.
Materials and Methods

An observational multicenter prospective study was conducted between December 2015 and September 2016. Patients with at least 12-months of follow-up after RRP were included. The study protocol was previously approved by our Institutional Ethics Committee. All of the included patients signed an informed consent before starting the study.

Uroflowmetry and the IPSS were used for the assessment of LUTS. A maximum urinary flow (Qmax) ≥ 15 ml/s was interpreted as normal, and ≤ 10 ml/s as abnormal; it was interpreted as equivocal with a Qmax between 10 and 15 ml/s or voided volume (VV) < 125 mL. These last two categories were unified to carry out a bivariate analysis and the analysis of correlation and concordance, and were classified with the purpose of comparing normal versus non-normal uroflowmetry.

The statistical analysis was performed using STATA 14 software (Statacorp, College Station, TX, USA). We used means and standard deviations (SDs) for quantitative variables; these were analyzed using the Student t-test or the Mann Whitney U-test, according to the distribution of the variables. For categorical variables, we used the chi-squared test. A univariate logistic regression was performed to establish an association between the IPSS and the uroflowmetry; for this analysis, urinary symptoms were classified as the presence of each symptom in ≥ 50% of the time in the previous month versus < 50% of the time, reported by the patient.

For nocturia, the presence of > 2 episodes per night was compared with ≤ 2. In the case of quality of life, an association was established between feeling delighted, pleased, or mostly satisfied and feeling indifferent, mostly dissatisfied, unhappy, or terrible with their voiding pattern.

A p-value < 0.05 was considered statistically significant. We evaluated the association between IPSS and the uroflowmetry using the Pearson correlation coefficient (r) and the Cohen kappa coefficient (k). The Bonferroni correction was used in the case of multiple comparisons.

Results

A total of 90 patients with prostate cancer who underwent RRP were evaluated, with a mean follow-up of 54.6 months (SD = 27.52). The mean age was 65 years old (SD = 6.85). At the time of the last control, the mean body mass index (BMI) was 20.6 Kg/m2 (SD = 5.09).

International Prostate Symptom Score

All of the patients answered 100% of the questionnaire. The mean IPSS was 7.41 (SD = 6.29); 60.0% (n = 54) were asymptomatic or had mild symptoms (IPSS 0–7), 33.3% (n = 30) had moderate symptoms (IPSS 8–19), and 6.7% (n = 6) had severe symptoms (IPSS 20–35).

Table 1 shows the frequency and severity of the symptoms of the patients. The most frequent and severe symptoms were nocturia, incomplete emptying, and weak stream. In contrast, the symptoms reported less frequently and with less severity were straining and intermittency. Regarding the quality of life, 63.4% of the patients reported that they felt very satisfied or delighted with their voiding pattern (Table 2).

Uroflowmetry

A total of 50% (n = 45) of the patients obtained a normal result in the uroflowmetry. The test was interpreted as abnormal (n = 11; 12.2%) or equivocal (n = 34; 37.8%). The mean Qmax was 19.87 ml/s (SD = 11.63), the mean average flow (Qav) was 11.31 ml/s (SD = 7.02), and the mean of VV was 323.1 mL (SD = 183.7).

There was an inverse, weak, and statistically significant correlation between the IPSS and the Qmax and Qav (Figure 1).

We also found that patients with an abnormal/equivocal result in uroflowmetry had a mean of 9.31 (SD = 7.03) points in the IPSS versus 5.51 (SD = 4.82) in patients with a normal result in the uroflowmetry (p < 0.01).

Table 2 Quality of life associated with urinary symptoms

<table>
<thead>
<tr>
<th>Personal Satisfaction</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delighted</td>
<td>14 (15.6)</td>
</tr>
<tr>
<td>Pleased</td>
<td>43 (47.8)</td>
</tr>
<tr>
<td>Mostly Satisfied</td>
<td>15 (16.7)</td>
</tr>
<tr>
<td>Indifferent</td>
<td>4 (4.4)</td>
</tr>
<tr>
<td>Mostly Dissatisfied</td>
<td>8 (8.9)</td>
</tr>
<tr>
<td>Unhappy</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Terrible</td>
<td>4 (4.4)</td>
</tr>
</tbody>
</table>

Table 3 Correlation coefficient between the uroflowmetry and the International Prostate Symptom Score

<table>
<thead>
<tr>
<th>Uroflowmetry parameters</th>
<th>IPSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qmax (r, p)</td>
<td>-0.30 (0.02)</td>
</tr>
<tr>
<td>Qav (r, p)</td>
<td>-0.29 (0.03)</td>
</tr>
<tr>
<td>VV (r, p)</td>
<td>-0.26 (0.07)</td>
</tr>
</tbody>
</table>

Table 1 Severity of urinary symptoms according to the International Prostate Symptom Score

<table>
<thead>
<tr>
<th>Urinary Symptoms</th>
<th>0–1</th>
<th>2–3</th>
<th>4–5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete emptying (n, %)</td>
<td>63 (70.0)</td>
<td>12 (13.4)</td>
<td>15 (16.6)</td>
</tr>
<tr>
<td>Frequency (n, %)</td>
<td>61 (67.8)</td>
<td>22 (24.4)</td>
<td>7 (7.8)</td>
</tr>
<tr>
<td>Intermittency (n, %)</td>
<td>82 (91.1)</td>
<td>3 (3.4)</td>
<td>5 (5.5)</td>
</tr>
<tr>
<td>Urgency (n, %)</td>
<td>68 (75.6)</td>
<td>14 (15.5)</td>
<td>8 (8.9)</td>
</tr>
<tr>
<td>Straining (n, %)</td>
<td>84 (93.4)</td>
<td>4 (4.4)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Weak stream (n, %)</td>
<td>59 (65.6)</td>
<td>20 (22.2)</td>
<td>11 (12.2)</td>
</tr>
<tr>
<td>Nocturia (n, %)</td>
<td>57 (63.3)</td>
<td>15 (16.7)</td>
<td>18 (20.0)</td>
</tr>
</tbody>
</table>

Abbreviation: IPSS, International Prostate Symptom Score.

r = Pearson correlation coefficient; p = p value.
Also, feeling delighted, pleased or mostly satisfied with their voiding pattern had an inverse association with the finding of abnormal or equivocal uroflowmetry (►Table 4).

### Agreement

The Pearson correlation coefficient between the IPSS and the Qmax was - 0.30 \( (p = 0.02) \) (►Fig. 1), - 0.29 \( (p = 0.03) \) between the IPSS and the mean urinary flow rate, and - 0.026 \( (p = 0.07) \) between the IPSS and VV.

The level of agreement achieved was 61.1\% \( (k = 0.22, p = 0.04) \) between mild symptoms in the IPSS versus moderate-to-severe symptoms and the results of normal uroflowmetry versus abnormal/equivocal uroflowmetry. This suggests that, despite the fact that most studies report improvement in LUTS after RRP, \(^{10}\) the number of patients who continue with symptoms is not negligible and is a problem that should be addressed, considering the important effect on the quality of life suffered by these patients.

Several studies have shown that subjective urinary symptoms have a weak correlation or even have no correlation with objective measures, consistent with the results of our study.\(^{17}\) This occurs because the origin of LUTS may have multiple causes, especially in men > 45 years old, the age at which most of these studies have been performed. Among these other causes, we find bladder dysfunction or urethral stricture.\(^{11,15,17}\) Specifically in the case of a patient after an RRP, the incompetent sphincter or urethral stricture of anastomosis can cause these LUTS. However, the urethral stricture can show more correlation between uroflowmetry results and LUTS, since there is outlet obstruction.

A study published by Ezz el Din et al\(^{14}\) with a population of 803 patients found a weak and statistically significant correlation between the IPSS and the result of uroflowmetry, suggesting that better noninvasive tools are needed for the evaluation of these symptoms, which is similar to our results. However, their study focused on patients with LUTS and benign prostatic growth, not on patients with prostate cancer who underwent RRP.

In our study, although the correlation was weak, the agreement was acceptable. Although there are studies that evaluate the agreement between the IPSS and uroflowmetry,
there are no studies of this correlation in patients after RRP. Considering our results, we believe that performing the uroflowmetry and the IPSS in conjunction can provide relevant clinical information about these patients.

**Conclusion**

Most of the patients after RRP were asymptomatic or had mild LUTS, and ~ 50% had normal uroflowmetry. Patients with an abnormal/equivocal result in the uroflowmetry had a mean IPSS in the range of moderate LUTS compared with patients with a normal uroflowmetry who had a mean IPSS in the range of mild symptoms. The IPSS and the uroflowmetry were inversely and weakly correlated, but the agreement between these tests was acceptable. We consider that although the IPSS cannot replace uroflowmetry, and vice-versa, these tests are complementary and may be useful tools in the evaluation of patients with LUTS after RRP.

**Conflicts of Interests**

The authors have no conflicts of interests to declare.

**Acknowledgments**

We thank our colleagues from Hospital Universitario San Ignacio, Fundación Cardioinfantil and Hospital Universitario Fundación Santa Fé who provided insight and expertise that greatly assisted the research.

**References**